Michael Root, MD, PhD

Contact Dr. Root

233 S. 10th Street
Room 802
Philadelphia, PA 19107

(215) 503-4564
(215) 923-2117 fax

Most Recent Peer-reviewed Publications

  1. Characterization of resistance to a potent d-peptide HIV entry inhibitor
  2. Complex interplay of kinetic factors governs the synergistic properties of HIV-1 entry inhibitors
  3. Site-Specific Polymer Attachment to HR2 Peptide Fusion Inhibitors against HIV-1 Decreases Binding Association Rates and Dissociation Rates Rather Than Binding Affinity
  4. Receptor Activation of HIV-1 Env Leads to Asymmetric Exposure of the gp41 Trimer
  5. Potent and Broad Inhibition of HIV-1 by a Peptide from the gp41 Heptad Repeat-2 Domain Conjugated to the CXCR4 Amino Terminus
  6. Evaluation of the efficiency of human immune system reconstitution in NSG mice and NSG mice containing a human HLA.A2 transgene using hematopoietic stem cells purified from different sources
  7. Mechanism of multivalent nanoparticle encounter with HIV-1 for potency enhancement of peptide triazole virus inactivation
  8. Polyvalent side chain peptide-synthetic polymer conjugates as HIV-1 entry inhibitors
  9. Nucleoporin Nup50 stabilizes closed conformation of armadillo repeat 10 in importin α5
  10. Design of a potent D-peptide HIV-1 entry inhibitor with a strong barrier to resistance
  11. Asymmetric deactivation of HIV-1 gp41 following fusion inhibitor binding
  12. Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil
  13. Topical application of entry inhibitors as "virustats" to prevent sexual transmission of HIV infection
  14. Neutralization of Botulinum neurotoxin by a human monoclonal antibody specific for the catalytic light chain
  15. Hybridoma populations enriched for affinity-matured human IgGs yield high-affinity antibodies specific for botulinum neurotoxins
  16. A human monoclonal antibody that binds serotype A botulinum neurotoxin
  17. C34, a membrane fusion inhibitor, blocks HIV infection of Langerhans cells and viral transmission to T cells
  18. Kinetic dependence to HIV-1 entry inhibition
  19. HIV-1 gp41 as a target for viral entry inhibition
  20. Targeting therapeutics to an exposed and conserved binding element of the HIV-1 fusion protein